Israel Makov

Israel Makov is retiring upon the completion of his current term post the company's Annual General Meeting after having led the Mumbai-based company for ten years.

Eyeing over $300mn R&D spend; Ranbaxy to delist: Sun Pharma

The merger has fortified Sun Pharma‘s position as the world‘s fifth-largest specialty generic pharmaceutical company and the top Indian Pharma company with significant lead in market share.

Can divest good assets ASAP: Sun Pharma on CCI order

Sun Pharma chairman Israel Makov says the company has started the day after the CCI order. "We are divesting good assets, we are not divesting bad assets and you have a lot of buyers for good assets," he said.

Indian pharma cos welcome 'outsiders' to up global presence

Last few months saw some high profile changes in the managements of Indian pharma companies. Entirely promoter-controlled companies giving way to professional managements brought in from top multinationals to drive global ambitions, reports CNBC-TV18's Archana Shukla.

Sun Pharma Q4 cons PAT up 85% at Rs 820cr

Sun Pharmaceutical Industries has announced its fourth quarter results. The company's Q4 consolidated net profit was up85% at Rs 820 crore versus Rs 443 crore, year-on-year, YoY.